|
|
|
ASCO GU 2026 Preview: Trials in Bladder and Upper Tract Cancer
|
Ashish Kamat, MD, MBBS, and Petros Grivas, MD, PhD
Petros Grivas previews ASCO GU 2026, highlighting EV-304/KEYNOTE-B15 comparing perioperative enfortumab vedotin plus pembrolizumab to neoadjuvant gemcitabine-cisplatin in cisplatin-eligible patients.
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Highlights to Anticipate from the Upcoming ASCO GU26 Cancers Symposium
|
|
|
|
|
Thursday, February 26, 2026
|
|
| Oral Abstract Session A: Prostate Cancer - 0805-0945 PST
|
|
|
|
|
Final Overall Survival Results From the EORTC 1333/PEACE-3 Trial: Enzalutamide With or Without Radium-223 in Metastatic Castration-Resistant Prostate Cancer there any ongoing trials involving new therapies?
Presented By: Enrique Gallardo, MD
|
|
|
|
|
Overall Survival From the Phase 2 Trial of Abiraterone, Olaparib, or Abiraterone + Olaparib in First-Line McRpc With DNA Repair Defects (BRCAAway)
Presented By: Maha Hussain, MD
|
|
|
|
|
Oral Abstract Discussant
Presented By: Evan Yu, MD
|
|
|
|
|
Hormone Therapy Use and Duration With Post-Operative Radiotherapy for Recurrent Prostate Cancer: An Individual Patient Data Meta-Analysis
Presented By: Amar Kishan, MD
|
|
|
|
|
Fifteen-Year Survival Analysis From the ASCENDE-RT Randomized Trial of External Beam Boost Versus Brachytherapy Boost in Localized Prostate Cancer
Presented By: Scott Tyldesley, MD, MPA, ABR, FRCPC
|
|
|
|
|
Oral Abstract Discussant
Presented By: Bridget F. Koontz, MD, FASTRO
|
|
|
|
|
| Keynote Address - 1415-1500 PST
|
|
|
|
|
Reimaging Cancer Research and Care in the Age of Artificial Intelligence
Presented By: Eliezer Mendel Van Allen, MD
|
|
|
|
|
| Rapid Oral Abstract Session A: Prostate Cancer - 1700-1745 PST
|
|
|
|
|
ADT and Radiotherapy With or Without Cabazitaxel in Very-High Risk Localized Prostate Cancer: First Results of the PEACE-2 Randomized Phase III Trial
Presented By: Karim Fizazi, MD, PhD
External Validation of a Digital Pathology-Based MMAI-Derived Prognostic Biomarker in the Randomized Phase
III CHHiP Trial
Presented By: Anna C. Wilkins, MD
Genomic Alterations and Pathologic Responses to Neooadjuvant
ARPI Doublets vs Docetaxel Triplets in the Genomic
Umbrella Neoadjuvant Study (GUNS)
Presented By: Martin Gleave, MD, BSc
|
|
|
|
|
|
|
|
|
|
Preliminary Phase 1 Dose Escalation Results of VIR-5500 (AMX-500), a Dual Masked PRO-XTEN T-Cell Engager, in mCRPC
Presented By: Johann De Bono, MD, CHB, MSc, PhD
|
|
|
|
|
HRQoL, Pain, and Symptomatic Skeletal Evens in the Phase 3 PSMAddition Study of 177Lu-PSMA-617 Combined With ADT and ARPI in Patients With PSMA-Positive mHSPC
Presented By: Michael Morris, MD, PhD
|
|
|
|
|
First-in-Human Assessment of 225Ac-PSMA-Trillium (BAY 3563254) in mCRPC: Dose-Escalation Results of the Phase 1 PAnTHa Study
Presented By: Fred Saad, MD, FRCS
|
|
|
|
|
SWOG S1602: A Phase III Randomized Trial To Evaluate BCG Strain Differences and Priming With Intradermal BCG Before Intravesical Therapy for BCG-Naïve High-Grade Non-Muscle Invasive Bladder Cancer (NCT #03091660)
Presented By: Robert S. Svatek, MD
|
|
|
|
|
|
Friday, February 27, 2026
|
|
| Oral Abstract Session B: Urothelial Carcinoma - 0810-0945 PST
|
|
|
|
|
Neoadjuvant and Adjuvant EV + Pembrolizumab for Participants With MIBC Who Are Eligible for Cisplatin: Randomized, Open-Label, Phase 3 KEYNOTE-B15 Study
Presented By: Matthew Galsky, MD
|
|
|
|
|
RC48G001: A Phase 2 Study of Disitamab Vedotin in HER2-Expressing Previously Treated Advanced UC
Presented By: Thomas Powles, MBBS, MRCP, MD
|
|
|
|
|
KEYNOTE-B15 and RC48G001 Discussant
Presented By: Tyler Stewart, MD
|
|
|
|
|
ctDNA To Guide Response-Adapted Bladder Preservation in MIBC: Integrated Analysis of the RETAIN Trials
Presented By: Pooja Ghatalia, MD
|
|
|
|
|
ctDNA-Guided Adjuvant Atezolizumab in MIBC: Exploratory Analysis of ctDNA Dynamics in the IMvigor011 Trial
Presented By: Thomas Powles, MBBS, MRCP, MD
|
|
|
|
|
RETAIN and IMvigor011 Discussant
Presented By: Jonathan Wright, MD, MS, FACS
|
|
|
|
|
| Poster Session B: Prostate Cancer and Urothelial Carcinoma - 1130-1245 PST
|
|
|
|
|
Association of Non-Luminal Subtype With Overall Survival in High-Risk Non-Muscle Invasive Bladder Cancer Patients: Biomarker Results From the Bladder Cancer Prognosis Programme
Presented By: Joep de Jong, MD, PhD
|
|
|
|
|
| Rapid Oral Abstract Session B: Urothelial Carcinoma - 1600-1645 PST
|
|
|
|
|
KEYMAKER-U04 Substudy 04B: First-Line EV + Pembro-Based Immune Checkpoint Inhibitor Combinations for Advanced UC
Presented By: Avivit Peer, MD
Gemcitabine Intravesical System in Combination With Cetrelimab Versus Chemoradiotherapy in MIBC: SunRISe-2 Final Results
Presented By: Andrea Necchi, MD
Urinary Tumor DNA and ctDNA in Patients With MIBC Who Received Perioperativber Durvalumab in NIAGARA
Presented By: Michiel S. Van Der Heijden, MD, PhD
|
|
|
|
|
|
|
|
|
|
Pathological Outcomes and DFS in KEYNOTE-905: Neoadjuvant and Adjuvant EV + Pembro in Participants With MIBC Who Are Cisplatin-Ineligible
Presented By: Anders Ullen, MD
|
|
|
|
|
Updated Clinical Results and Associated Biomarkers From an Ongoing Phase 1 Study of FX-909, a First-in-Class Peroxisome Proliferator-Activated Receptor Gamma (PPARG) Inhibitor, in Patients With Advanced UC
Presented By: Matthew Galsky, MD
|
|
|
|
|
|
Saturday, February 28, 2026
|
|
| Oral Abstract Session C: Renal Cell Cancer and Testicular Cancer - 0810-0945 PST
|
|
|
|
|
Belzutifan + Lenvatinib Versus Cabozantinib for Advanced RCC After Anti-PD-(L)1 Therapy: Open-Label Phase 3 LITESPARK-011 Study
Presented By: Robert Motzer, MD
|
|
|
|
|
Adjuvant Pembrolizumab + Belzutifan Versus Pembrolizumab for Clear Cell RCC: The Randomized Phase 3 LITESPARK-022 Study
Presented By: Toni Choueiri, MD
|
|
|
|
|
|
More coverage to come — stay tuned throughout ASCO GU 2026
|
|
|
|
|
